引言近年来，局部晚期直肠癌（LARC）治疗策略发展迅速，全程新辅助治疗（total neoadjuvant ...

Background: Neoadjuvant chemoradiotherapy is currently the standard strategy for microsatellite stable (MSS) / mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC) patients. This ...

I MUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

Background: Neoadjuvant treatment with immune checkpoint inhibitors has shown remarkable responses in patients with deficient mismatch repair (dMMR) colorectal cancer. However, the optimal choice and ...

EMA committee recommends approval of BeOne Medicines’ Tevimbra to treat neoadjuvant/adjuvant NSCLC: San Carlos, California Wednesday, July 30, 2025, 12:00 Hrs [IST] BeOne Medici ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of the ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Key Takeaways Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant ...